Zervimesine Shows 86% Slowing of Decline in Dementia with Lewy Bodies Symptoms in Phase 2 Study
Summary
Cognition Therapeutics presented compelling Phase 2 data for its drug zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) at the AD/PD 2026 conference. The analysis from the SHIMMER study demonstrated an 86% slowing of decline on the NPI-12 index for neuropsychiatric symptoms compared to placebo. This is highly significant as DLB patients frequently experience severe neuropsychiatric symptoms, and many existing antipsychotics are contraindicated due to severe side effects. Zervimesine's unique mechanism offers a potentially tolerable and disease-modifying treatment option for a critical unmet medical need. The company recently announced plans to develop zervimesine for DLB psychosis following a Type C meeting with the FDA, and this robust Phase 2 data strongly supports that strategic path. Investors will now be looking for further regulatory guidance and the initiation of pivotal trials.
At the time of this announcement, CGTX was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $95.3M. The 52-week trading range was $0.22 to $3.83. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.